- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01384747
Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)
June 19, 2018 updated by: Seung-Jung Park
A Randomized, Double-blind Study of Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease
- Fimasartan will be more beneficial in stabilizing the plaque vulnerability compared to control group in deferred coronary lesions.
- Fimasartan will be more beneficial in reducing total plaque volume compared to control group in deferred coronary lesions.
- Fimasartan will be more beneficial in reducing functional impairment of stenotic lesions (assessed by FFR:Fractional Flow Reserve) in deferred coronary lesions.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Prospective, double-blind, randomized clinical study with enrollment of patients over at least 18 years of age who require coronary angiography for a clinical indication with hypertension defined as systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg.
Inclusion requires at least one deferred coronary lesion with 1) visually-estimated angiographic %diameter stenosis 20-50% or 2) %diameter stenosis >50% without any evidence of inducible ischemia.
The target vessel for IVUS interrogation must not have undergone angioplasty (deferred lesion) nor have more than 50% luminal narrowing throughout a target segment.
Patients meeting inclusion criteria without any exclusion criteria will be randomized 1:1 (Fimasartan 60-120 mg vs placebo).
All subjects will be followed up at 1 year for serial VH-IVUS and conventional IVUS evaluation.
Also, OCT sub-study will be performed in selected patients with lesions at least 20 mm distally located from coronary ostium.
All patients will be blindly assigned to control and Fimasartan once daily as 1:1 ratio and are prescribed for 1year.
Study Type
Interventional
Enrollment (Actual)
186
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gwangju, Korea, Republic of, 501-757
- Chonnam National University Hospital
-
Seoul, Korea, Republic of, 138-736
- Asan Medical Center
-
Ulsan, Korea, Republic of, 682-714
- Ulsan University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 84 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Hypertensive patients (systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg) or medically treated hypertension with normal blood pressure who undergo coronary angiography with clinical indications
- 18 < Age < 85
- Patient who has received informed consent
- at least one deferred coronary lesion with 1) visually-estimated angiographic %diameter stenosis 20-50% or 2) %diameter stenosis >50% without any evidence of inducible ischemia (FFR ≥ 0.8 or negative perfusion defect on thallium scan or negative treadmill test)
Exclusion Criteria:
- Planned cardiac surgery (e.g., CABG, valve repair or replacement, or aneurysmectomy) or planned major non-cardiac surgery within the study period
- Planned performance of PCI or CABG in the target vessel or its branches containing the index
- Evidence of congestive heart failure, or left ventricular ejection fraction < 40%
- Stroke or resuscitated sudden death in the past 6 months
- Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible)
- A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer
- Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study
- Significant renal disease manifested by serum creatinine > 1.5 mg/dL
- Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 3 times upper limit of normal)
- Active hepatitis B or C or carrier
- Hypotension (systolic blood pressure <90 mmHg)
- Patients already taking ACE inhibitors or ARBs
- Patients with STEMI requiring primary PCI
- Patients pregnant or breast-feeding or child-bearing potential
- Patients who are lack of intention for effective contraception
- Patients with history of previous enrollment into a clinical trials within 3 months
- Allergic or contraindicated to Angiotensin II antagonists
- History of any arterial bypass or angioplastic intervention involving the target vessel
- Luminal narrowing in the left main > 50% by visual inspection of angiogram
- Visually-estimated angiographic reference segment diameter of <2.75mm or >4.0 mm
- Presence of thrombus or complex plaque morphology in the target vessel that suggests a high likelihood of distal embolism
- Severe tortuosity of the target vessel or any other anatomical reasons that the investigator deems
- Inappropriate for IVUS procedures. Vessel with thrombus (on GS-IVUS), moderate or severe calcification, angulation
- Culprit vessel in AMI
- RWMA (Regional Wall Motion Abnormality) or scar tissue in the territory subtended by the studied lesion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fimasartan
Initial dose will be started with 60mg per day.
At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
|
60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
Other Names:
|
Placebo Comparator: Placebo
Initial dose will be started with 60mg per day.
At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
|
60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in percent necrotic core (NC) volume of plaque by VH (Virtual Histology) in the "target segment" (within deferred vessel)
Time Frame: baseline and 1 year
|
baseline and 1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change of total atheroma volume (TAV) and percent atheroma volume (PAV) of the target segment and the most diseased 10-mm segment (normalized to different segment length) with the largest plaque volume
Time Frame: baseline and 1 year
|
baseline and 1 year
|
Percent change in minimal lumen area (MLA) in target segment
Time Frame: baseline and 1 year
|
baseline and 1 year
|
Change of absolute area or percentages (%) of each plaque VH composition (fibrotic, fibrofatty, dense calcium, necrotic core) at minimal lumen area (MLA) and largest necrotic core area within the target segment
Time Frame: baseline and 1 year
|
baseline and 1 year
|
Change of VH-IVUS (Intra Vascular UltraSound) detected plaque type from baseline
Time Frame: at 1 year
|
at 1 year
|
Change of percentage (%) of OCT (Optical Coherence Tomography)-defined TCFA (Thin Cap Fibrotic Atheroma) within the target segment from baseline
Time Frame: at 1 year
|
at 1 year
|
Change of composition of OCT-defined fibrous, fibro-calcific, and lipid-rich plaque within the target segment
Time Frame: baseline and 1 year
|
baseline and 1 year
|
Change of OCT-defined fibrous cap thickness, the presence of plaque disruption, calcification or intraluminal thrombus within the target segment
Time Frame: baseline and 1 year
|
baseline and 1 year
|
Change of FFR in target segment from baseline
Time Frame: at 1 year
|
at 1 year
|
systolic and diastolic blood pressure
Time Frame: at 1 year follow-up
|
at 1 year follow-up
|
Change in high sensitive CRP (C-Reactive Protein)from baseline
Time Frame: at 1 year
|
at 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2011
Primary Completion (Actual)
March 1, 2018
Study Completion (Actual)
March 1, 2018
Study Registration Dates
First Submitted
June 24, 2011
First Submitted That Met QC Criteria
June 28, 2011
First Posted (Estimate)
June 29, 2011
Study Record Updates
Last Update Posted (Actual)
June 20, 2018
Last Update Submitted That Met QC Criteria
June 19, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CVRF2011-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
This is not a publicly funded trial.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Fimasartan
-
Boryung Pharmaceutical Co., LtdCompleted
-
Boryung Pharmaceutical Co., LtdSeoul National University HospitalCompleted
-
Boryung Pharmaceutical Co., LtdSeoul National University Hospital; Kyungpook National University HospitalCompleted
-
Boryung Pharmaceutical Co., LtdYonsei University; Kyungpook National University HospitalCompletedEssential Hypertension | Hepatic ImpairmentKorea, Republic of
-
Boryung Pharmaceutical Co., LtdCompleted
-
Boryung Pharmaceutical Co., LtdCompleted
-
Boryung Pharmaceutical Co., LtdChonbuk National University Hospital; Samsung Medical Center; Asan Medical Center and other collaboratorsCompletedEssential HypertensionKorea, Republic of
-
Boryung Pharmaceutical Co., LtdCovanceCompletedEssential Hypertension
-
Boryung Pharmaceutical Co., LtdCompletedHypertensionKorea, Republic of
-
Seoul National University HospitalSamsung Medical Center; Chonnam National University Hospital; Korea University... and other collaboratorsUnknownCritical Stenosis of Aortic ValveKorea, Republic of